{"task_id": "6c995f541572f543", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 364/464)", "text": "vis, vertebra, femur, tibia) that\nOsteoporosis\n355\n\n--- Page 377 ---\nSPECIFIC ENTITIES (CONT\u2019D)\nextends by 1 cm/year. This is followed by imper\nfect bone repair, leading to bone expansion and\nsoftening ! pain, fracture, deformity, and rarely\nneoplastic transformation\n\u0002\nCLINICAL FEATURES\nusually asymptomatic in early\ndisease. Bone pain (achy, deep) and weakness\ndevelops later in the course, persists throughout\nthe day and at rest, and may be worse at night.\nBony deformity may lead to difficulties with\nweight bearing (femur, tibia), headaches and hear\ning loss (skull), and even neurological symptoms\nand paralysis (spine)\n\u0002\nDIAGNOSIS\n\" ALP is an excellent marker of disease\nextent and activity and can be used to follow\ntreatment. Bone scan and plain X rays can be\ndiagnostic. In \u2018\u2018mixed stage\u2019\u2019 disease, cortical thick\nening (hyperostosis) disorganized coarse trabecu\nlae (osteosclerosis), and bone expansion may be\nSPECIFIC ENTITIES (CONT\u2019D)\nseen. In advanced (\u2018\u2018burnt out\u2019\u2019) disease, bones are\nwidened and heterogeneously ossified\n\u0002\nTREATMENTS\nsupportive care. Treatments include\nbisphosphonates (alendronate 40 mg PO daily\n\u00036 months, risedronate 30 mg PO daily \u00032\nmonths, or zoledronate 5 mg IV), calcitonin\n50 100 U SC/IM daily \u00036 18 months (not as effec\ntive). Bisphosphonates can provide pain control,\nimprove skeletal scintigraphy, and sometimes heal\nosteolytic lesions. Indications for therapy include\nsymptoms related to active bone lesions (bone\npain, headache, back pain, any other neurological\nsyndromes,\nfissure\nfractures),\nprophylaxis\nin\nasymptomatic patients (weight bearing bones\ninvolved and likely to progress), and elective sur\ngery planned for pagetic site (e.g. hip replace\nment) and hypercalcemia\nNEJM 2006 355:6\nHypertension\nSee HYPERTENSION (p. 57)\nHyperlipidemia\nSee HYPERLIPIDEMIA (p. 61)\nAmenorrhea\nDIFFERENTIAL DIAGNOSIS\nPRIMARY AMENORRHEA\n\u0002\nHYPOTHALAMIC DYSFUNCTION\nfunctional\n\u0002\nPITUITARY\nDYSFUNCTION\nprolactinoma, adeno\nmas, craniopharyngioma\n\u0002\nOVARIAN FAILURE\nTurner\u2019s syndrome (XO)\n\u0002\nUTERUS/VAGINA MALFORMATION\nandrogen insen\nsitivity syndrome (XY), agenesis of uterus/vagina\n(Mullerian agenesis), imperforated hymen\n\u0002\nOTHERS\nconstitutional delay, causes of second\nary amenorrhea\nSECONDARY AMENORRHEA\n\u0002\nPREGNANCY\n\u0002\nHYPOTHALAMIC SUPPRESSION\nphysiologic or emo\ntional stress, strenuous exercise, weight loss, anor\nexia nervosa, infiltrative disease (lymphoma,\nsarcoidosis)\n\u0002\nPITUITARY DISEASE\nprolactinoma, Sheehan\u2019s syn\ndrome, hypothyroidism\nDIFFERENTIAL DIAGNOSIS (CONT\u2019D)\n\u0002\nOVARIAN\nPCOS,\nmenopause\n(chemotherapy,\nradiation, birth control pills), premature ovarian\nfailure\n\u0002\nUTERUS\nAsherman syndrome\nPATHOPHYSIOLOGY\nDEFINITION OF AMENORRHEA\n\u0002\nPRIMARY AMENORRHEA\nabsence of menstruation by\nage 14 with the absence of secondary sexual char\nacteristics or absence of menstruation by age 16 with\nthe presence of secondary sexual characteristics\n\u0002\nSECONDARY AMENORRHEA\ncessation of menses for\nat least 3 consecutive cycles or 6 months\nCLINICAL FEATURES\nHISTORY\ncharacterize amenorrhea (onset, dura\ntion, previous menstruation), pregnancy and related\nsymptoms, puberty milestones, headaches, visual\n356\nAmenorrhea", "text_length": 3145, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 364/464)", "type": "chunk", "chunk_index": 363, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.750773", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.751526", "status": "complete", "chunks_added": 2}